ADC Platform

CAP-0121 is an illudofulvene designed for administration as monotherapy

  • it has 4X the potency of the first generation drug (irofulven)

  • it is now targeted at specific sub-populations (genetically defined cancers)

Califia has also developed different illudofulvenes

  • far too toxic for direct administration as a drug, but great for use an ADC payload

  • display a higher efficacy/toxicity ratio than MMA or DM1, leading ADC payloads

  • despite equipotency in the NCI screening platform, ~ 100 fold less toxic to animals

  • Califia has also developed unique antibody linkers

Together, these payloads and linkers should be attractive to companies developing ADCs or SMDCs

Summary: Why Califia’s Payloads?

  • Unique MOA: Inhibit transcription-coupled DNA repair

  • True nanomolar cytotoxic activity (not cytostatic) with a 2 hr exposure

  • Active against TCR competent cancers

  • Do not require enzymatic activation  

  • Versatility & small molecular weight (use with any linker)

  • Inexpensive to manufacture (even API material)

  • Truly active against MDR cancers (unlike existing payloads)

  • FDA/EMA review of payload/precursor manufacturing process

  • High therapeutic index & systemic toxicity limited to low platelets

  • Chemistry simple (2 to 4 steps vs > 12 with existing payloads)